Arsenic and ATRA for new APL patients
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of oral arsenic and ATRA for people newly diagnosed with acute promyelocytic leukemia (APL). It aims to see if this drug combo can treat the disease effectively without standard chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must be newly diagnosed with APL (a type of leukemia) and confirmed by genetic testing
- Age between 18 and 75 years old
- Good liver and kidney function (based on blood tests)
- Women must be postmenopausal, have had surgery to prevent pregnancy, use highly effective birth control, or have a partner who had a vasectomy
- No other active cancer or serious heart, lung, or liver conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether an oral version of arsenic trioxide works as well as the IV version for people with a certain type of leukemia called APL. It aims to confirm that taking the drug by mouth has similar safety and effectiveness.
This trial tests a new drug, QTX-2101, in people with acute promyelocytic leukemia (APL) that is low- or intermediate-risk. The study aims to see if the drug works and is safe for those who qualify.
This trial tests whether giving a combination of two oral medicines—realgar-indigo naturalis formula (RIF) and all-trans retinoic acid (ATRA)—early in treatment can help people with acute promyelocytic leukemia (APL), a specific type of blood cancer. The goal is to see if this approach works better than current standard care.
This trial studies how well a combination of tretinoin (ATRA) and arsenic trioxide (ATO)—with or without another antibody-like drug called gemtuzumab—treats people with newly diagnosed acute promyelocytic leukemia (APL). The goal is to see if these medicines work better together and are safe.
This trial tests if combining interferon-α with arsenic trioxide (ATO) can help people whose acute promyelocytic leukemia (APL) has stopped responding to arsenic treatment. If you have this type of leukemia that came back or didn't get better after arsenic therapy, this study may offer a new option.
This Phase 2 study tests an oral form of arsenic trioxide in people newly diagnosed with APL (a specific leukemia subtype). It aims to see how well this frontline treatment works and whether it can be given safely.
Hear when a new Acute Promyelocytic Leukemia (APL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.